IDEXX Announces CEO Succession
IDXXWESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the promotion of Michael (Mike) Erickson, PhD, to President and Chief Executive Officer, effective May 12, 2026, at which time Jonathan (Jay) Mazelsky, President and CEO, will transition to the role of Executive Chair of IDEXX’s Board of Directors (the “Board”). Mr. Mazelsky has announced his intention to retire from the Company immediately following the Comp
IDEXX Laboratories to Release 2025 Fourth Quarter and Full Year Financial Results
IDXXWESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2025 fourth quarter and full year financial results for Monday, February 2, 2026, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q4 2025 Earnings Snapshot through a link on
IDEXX Laboratories to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference
IDXX(NASDAQ:IDXX) WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that Jay Mazelsky, President and Chief Executive Officer, and Andrew Emerson, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025 from 1:50 pm – 2:25 pm (ET). A live audio webcast of the presentation will be available through a li
IDEXX Laboratories Announces Second Quarter Results
IDXXWESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced second quarter results. “Our innovation-driven strategy delivered robust global growth in the second quarter,” said Jay Mazelsky, President and Chief Executive Officer. "We saw exceptional momentum with IDEXX InVue Dx™ placements, exceeding expectations as veterinarians adopted this slide-free technology to streamline workflows and gain faster, more accurate
IDEXX Laboratories Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
IDXXLeerink Partners Maintains Outperform on IDEXX Laboratories, Raises Price Target to $580
IDXXThree Lawmakers Bought This Biotech Stock Before Supporting A Bill That Could Boost Its Value: It's Now Up 44%
IDXXThree U.S. lawmakers have disclosed recent purchases of a pet healthcare company just weeks before supporting a biotech bill.
IDEXX Unveils Catalyst Cortisol Test To Support Early Detection And Ongoing Management Of Canine Endocrine Disorders
IDXXWhat Does the Market Think About IDEXX Laboratories?
IDXXIf You Invested $1000 In This Stock 15 Years Ago, You Would Have This Much Today
IDXX$1000 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
IDXXStifel Maintains Hold on IDEXX Laboratories, Raises Price Target to $510
IDXXIs the Market Bullish or Bearish on IDEXX Laboratories?
IDXXMorgan Stanley Maintains Overweight on IDEXX Laboratories, Raises Price Target to $558
IDXXIDEXX Laboratories Raises FY2025 GAAP EPS Guidance from $11.74-$12.24 to $11.93-$12.43 vs $11.91 Est; Raises FY2025 Sales Guidance from $4.05B-$4.17B to $4.09B-$4.21B vs $4.12B Est
IDXXIDEXX Laboratories Q1 Adj. EPS $2.91 Beats $2.85 Estimate, Sales $998.43M Beat $998.15M Estimate
IDXXHere's How Much $100 Invested In IDEXX Laboratories 10 Years Ago Would Be Worth Today
IDXXA Look Into IDEXX Laboratories Inc's Price Over Earnings
IDXXStifel Maintains Hold on IDEXX Laboratories, Lowers Price Target to $420
IDXXHow Is The Market Feeling About IDEXX Laboratories?
IDXXU.S. Judge Dismisses Most Of Consumer Lawsuit Against Idexx Laboratories Over Veterinary Service Prices
IDXXDecoding 5 Analyst Evaluations For IDEXX Laboratories
IDXX$1000 Invested In This Stock 10 Years Ago Would Be Worth $5,600 Today
IDXXPiper Sandler Reiterates Neutral on IDEXX Laboratories, Lowers Price Target to $435
IDXXBarclays Maintains Overweight on IDEXX Laboratories, Lowers Price Target to $481
IDXXIdexx Laboratories Adjusts Guidance As Q3 Revenue Growth Slows, Analyst Notes Fewer Veterinary Visits, Looks Towards Long-Term Growth
IDXXIdexx Laboratories posted a Q3 EPS of $2.79, beating estimates, though revenue of $975.54 million fell short. Veterinary trends and guidance update key 2024 outlook.
IDEXX Laboratories Expects 2024 Adjusted EPS Of $10.37-$10.53 Versus Prior Guidance Of $10.31-$10.59 And Consensus Of $10.56
IDXXIDEXX Laboratories Expects 2024 Revenue Of $3.865B-$3.89B Versus Prior Guidance Of $3.885B-$3.945B And Consensus Of $3.92B
IDXXIDEXX Laboratories Q3 2024 Adj EPS $2.79 Beats $2.68 Estimate, Sales $975.54M Miss $979.18M Estimate
IDXX$100 Invested In This Stock 15 Years Ago Would Be Worth $2,500 Today
IDXXRecap: IDEXX Laboratories Q1 Earnings
IDXXIDEXX Laboratories (NASDAQ:IDXX) reported its Q1 earnings results on Wednesday, May 4, 2022 at 06:30 AM.
Here's what investors need to know about the announcement.
IDEXX Laboratories Sees FY22 Sales $3.39B-$3.465B Vs. $3.54B Est.
IDXXIDEXX Laboratories Q1 EPS $2.27 Beats $2.26 Estimate, Sales $837.00M Miss $839.72M Estimate
IDXXEarnings Preview For IDEXX Laboratories
IDXXIDEXX Laboratories (NASDAQ:IDXX) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement.
Analysts estimate that IDEXX Laboratories will report an earnings per share (EPS) of $2.26.
IDEXX Laboratories Earnings Conference Call Is Coming Up, Here's What You Need To Know
IDXXIDEXX Laboratories (NASDAQ:IDXX) will host a conference call at 08:30 AM ET on May 4, 2022, to discuss Q1 2022 earnings results.
